<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04729309</url>
  </required_header>
  <id_info>
    <org_study_id>BP41811</org_study_id>
    <nct_id>NCT04729309</nct_id>
  </id_info>
  <brief_title>Mass Balance and Absolute Bioavailability Study of RO7049389 in Healthy Volunteers</brief_title>
  <official_title>Open-Label Study to Investigate the Mass Balance and Absolute Bioavailability of a Single Oral Dose of [14C]-Labeled RO7049389 or RO7049389 and an Intravenous Micro-Dose of [13C]-Labeled RO7049389 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to characterize the mass balance, absolute bioavailability,&#xD;
      route and rates of elimination of RO7049839.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 31, 2021</start_date>
  <completion_date type="Actual">June 14, 2021</completion_date>
  <primary_completion_date type="Actual">June 14, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Dose Excreted in Urine</measure>
    <time_frame>Up to Day 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Dose Excreted in Feces</measure>
    <time_frame>Up to Day 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute Oral BA for RO7049389</measure>
    <time_frame>Up to Day 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of RO7049389</measure>
    <time_frame>Up to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve from Time Zero to Last Measurable Concentration (AUClast) of RO7049389</measure>
    <time_frame>Up to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Concentration-Time Curve from Time Zero to Infinity (AUC0-inf) of RO7049389</measure>
    <time_frame>Up to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) of RO7049389</measure>
    <time_frame>Up to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL/F) of RO7049389</measure>
    <time_frame>Up to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) of RO7049389</measure>
    <time_frame>Up to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Clearance (CLr) of RO7049389</measure>
    <time_frame>Up to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount Excreted in Urine (Ae) of RO7049389</measure>
    <time_frame>Up to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-Life (T1/2) of RO7049389</measure>
    <time_frame>Up to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs)</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Mass Balance (MB) Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive oral [14C] RO7049389 under fasted conditions, followed by intravenous IV [13C] after a two-hour period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Absolute Bioavailability (BA) Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Periods 1 and 2, participants will receive oral [12C] RO7049389 under fasted conditions, followed by IV [13C] RO7049389. There is a minimum 7-day washout between periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[12C] RO7049389</intervention_name>
    <description>Participants will receive oral [12C] RO7049389.</description>
    <arm_group_label>Absolute Bioavailability (BA) Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[13C] RO7049389</intervention_name>
    <description>Participants will receive IV [13C] RO7049389.</description>
    <arm_group_label>Absolute Bioavailability (BA) Cohort</arm_group_label>
    <arm_group_label>Mass Balance (MB) Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C] RO7049389</intervention_name>
    <description>Participants will receive an oral suspension of [14C] RO7049389.</description>
    <arm_group_label>Mass Balance (MB) Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Caucasian (must have Caucasian parents and grandparents) or East Asian (must have&#xD;
             Chinese, Korean, or Japanese parents and grandparents)&#xD;
&#xD;
          -  Body mass index between 18 to 30 kg/m^2 (inclusive) and a weight range of 50 kg to 100&#xD;
             kg (inclusive) at screening&#xD;
&#xD;
          -  For women of childbearing potential: agree to use two methods of contraception, with&#xD;
             at least one method considered as highly effective during the study and for at least&#xD;
             90 days after the last dose of study drug&#xD;
&#xD;
          -  For men: agree to remain abstinent (refrain from heterosexual intercourse) or agree to&#xD;
             use contraceptive measures, and agree to refrain from donating sperm during the&#xD;
             treatment period and for at least 90 days after the last dose of study drug&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women, and male participants with partners who are pregnant or&#xD;
             lactating&#xD;
&#xD;
          -  History or symptoms of any clinically significant cardiovascular, respiratory,&#xD;
             hepatic, renal, gastrointestinal, endocrine, hematological, oncologic, or neurological&#xD;
             disorders capable of significantly altering the absorption, metabolism, or elimination&#xD;
             of drugs; of constituting a risk when taking the study treatment; or of interfering&#xD;
             with the interpretation of data&#xD;
&#xD;
          -  Personal history or family history of congenital long QT interval (QT) syndrome and/or&#xD;
             cardiac sudden death&#xD;
&#xD;
          -  History of Gilbert syndrome&#xD;
&#xD;
          -  Participants who have had significant acute infection, e.g. influenza, local&#xD;
             infection, acute gastrointestinal (GI) symptoms, or any other clinically significant&#xD;
             illness within two weeks of dose administration&#xD;
&#xD;
          -  Any confirmed significant reactions (urticaria or anaphylaxis) against any drug, or&#xD;
             multiple drug allergies&#xD;
&#xD;
          -  Any clinically significant concomitant diseases or conditions that could interfere&#xD;
             with the conduct of the study, or in the opinion of the Investigator, would pose an&#xD;
             unacceptable risk to the participant in this study&#xD;
&#xD;
          -  Taking any herbal medications or substances, supplements (including vitamins),&#xD;
             traditional Chinese medicines, prescription medicine, or over-the-counter medications&#xD;
             within 14 days of first dosing or within 5 times the elimination half-life of the&#xD;
             medication prior to first dosing, whichever is longer&#xD;
&#xD;
          -  History of having received any systemic anti-neoplastic (including radiation) or&#xD;
             immune-modulatory treatment (including systemic oral or inhaled corticosteroids) 6&#xD;
             months prior to the first dose of study drug or the expectation that such treatment&#xD;
             will be needed at any time during the study&#xD;
&#xD;
          -  Are currently enrolled in or have participated in any other clinical study involving&#xD;
             an investigational product or in any other type of medical research within the last 90&#xD;
             days (or within 5 half-lives of the investigational product, whichever is longer)&#xD;
&#xD;
          -  Donation or loss of blood or blood products in excess of 500 mL within 3 months of&#xD;
             screening&#xD;
&#xD;
          -  Evidence of current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)&#xD;
             infection&#xD;
&#xD;
          -  Hepatitis A, B, C, D, or E or HIV infection&#xD;
&#xD;
          -  History of drug or alcohol abuse in the past 2 years&#xD;
&#xD;
          -  Regular alcohol consumption in males &gt; 21 units per week and in females &gt; 14 units per&#xD;
             week (1 unit = 1/2 pint of beer, or a 25 mL shot of 40% spirit, 1.5 to 2 units = 125&#xD;
             mL glass of wine, depending on type)&#xD;
&#xD;
          -  Use of &gt; 5 cigarettes or equivalent nicotine-containing product per day prior to&#xD;
             screening&#xD;
&#xD;
        Exclusion Criteria for Mass Balance Cohorts&#xD;
&#xD;
          -  Regular work with ionizing radiation or radioactive material&#xD;
&#xD;
          -  Radiation exposure, including that from the present study, excluding background&#xD;
             radiation but including diagnostic X-rays and other medical exposures, exceeding 5 mSv&#xD;
             in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker,&#xD;
             as defined in the Ionising Radiation Regulations 2017, shall participate in the study&#xD;
&#xD;
          -  Exposure to radiation for diagnostic reasons (except dental X-rays and plain X-rays of&#xD;
             thorax and bony skeleton [excluding spinal column]), during work, or during&#xD;
             participation in a medical trial in the previous year&#xD;
&#xD;
          -  History of gastrointestinal (GI) surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quotient Sciences</name>
      <address>
        <city>Nottingham</city>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 26, 2021</study_first_submitted>
  <study_first_submitted_qc>January 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2021</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

